Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
Novartis has published data showing Cosentyx (secukinumab) remains better than Janssen's Stelara (ustekinumab) in achieving sustained skin clearance at 52 weeks for adults with moderate-to-severe psoriasis. 7 March 2016
Pharmaceutical
Spain’s leading drugmaker Almirall discussed its strategy with The Pharma Letter’s local correspondent, explaining why it has moved out of the respiratory sector to focus on dermatology. 23 February 2016
Pharmaceutical
Mid-sized Japanese drugmaker Otsuka Pharmaceutical has inked a licensing deal with independent US drugmaker Medimetriks Pharmaceuticals, granting Medimetriks exclusive development and commercialization rights for OPA-15406 in the USA and Puerto Rico. 9 February 2016
Pharmaceutical
French independent pharma company Pierre Fabre today announced the launch of a new fund to accelerate the clinical development of new products in oncology and dermatology. 3 February 2016
Pharmaceutical
Almirall says it has exercised a call option to acquire 100% of the share capital of ThermiGen, a privately held USA-based medical aesthetics technology company and a developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications. 1 February 2016
Pharmaceutical
UK pharma major GlaxoSmithKline has informed Switzerland’s Basilea that it has elected to discontinue its US alitretinoin program. 22 January 2016
Pharmaceutical
The US Food and Drug Administration has approved Swiss pharma giant Novartis’ Cosentyx (secukinumab) for the treatment of two new indications - adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). 18 January 2016
Pharmaceutical
Allergan yesterday announced that it has acquired Anterios, a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products. 8 January 2016
Pharmaceutical
India-based Vyome Biosciences, on Thursday said the US Food and Drug Administration has accepted its Investigational New Drug (IND) application for its lead program VB 1953, a topical therapeutic candidate to treat acne. 7 January 2016
Pharmaceutical
French pharmaceutical company Ipsen on Wednesday said it has expanded the current distribution agreement for Dysport, with partner Galderma, in aesthetic indications to some Asia-Pacific territories. 6 January 2016
Generics
Ireland-incorporated Perrigo has said it will acquire a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals, a subsidiary of Rouses Point Pharmaceuticals. 18 December 2015
Pharmaceutical
Canadian drug maker Valeant Pharmaceuticals has struck a deal with the biggest pharmacy chain in the US to sell its skin and eye medications at a discounted price. 16 December 2015
Pharmaceutical
Pharma companies looking to developing innovative treatments from natural products will be given access to the world’s largest private collection of plants thanks to a unique project launched by French company Pierre Fabre. 8 December 2015
Pharmaceutical
The German Institute for Quality and Efficiency in Health Care (IQWiG), in a second dossier assessment of Swiss pharma giant Roche’s cancer drug Perjeta (pertuzumab) resulted in a survival advantage for certain patients taking the drug and hence for a hint of a major added benefit. 4 December 2015
Biotechnology
India-based Vyome Biosciences plans a regulatory filing by the end of the year with US Food and Drug Administration for its lead molecule (VB 1953), which targets the vast drug resistant acne prescription market, co-founder and chief executive N Venkat told The Pharma Letter in an exclusive interview. 30 November 2015
article
In another acquisition move, Spain’s largest pharma company Almirall has signed an agreement to acquire 100% of the share capital of the Switzerland-headquartered Poli Group Holdings. 30 November 2015
Pharmaceutical
UK specialty drugmaker Alliance Pharma has entered into a conditional agreement with Sinclair IS Pharma to acquire certain assets and businesses principally focused on dermatology. 26 November 2015
Pharmaceutical
Spanish pharma company Almirall has bought the rights to two dermatology products from Stiefel – a GSK affiliate - in exchange for distribution rights to Toctino (alitretinoin) and an undisclosed cash payment, it has been announced. 23 November 2015
Pharmaceutical
Japan’s Taiho Pharmaceutical has submitted an application for approval of the manufacture and marketing of TAC-202 (bilastine), an oral anti-allergy drug, to the Japanese Ministry of Health, Labor and Welfare. 16 November 2015
Pharmaceutical
Derma Sciences is to stop development of its drug aclerastide for diabetic foot ulcer healing following the advice of a Data Monitoring Committee (DMC). 13 November 2015
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze